The protective effect of Cloprostenol on ischemia/reperfusion injury in rat ovary: Histopathologic and immunohistochemically evaluation: An experimental study.

Autor: Karakus S; Department of Obstetrics and Gynecology, Faculty of Medicine, Cumhuriyet University, Sivas, Turkey. Electronic address: karakussavas@yahoo.com.tr., Dogan HO; Department of Biochemistry, Faculty of Medicine, Cumhuriyet University, Sivas, Turkey., Özkaraca M; Department of Pathology, Faculty of Veterinary Medicine, Cumhuriyet University, Sivas, Turkey.
Jazyk: angličtina
Zdroj: Transplant immunology [Transpl Immunol] 2024 Oct; Vol. 86, pp. 102108. Date of Electronic Publication: 2024 Aug 14.
DOI: 10.1016/j.trim.2024.102108
Abstrakt: OBJECTıVES: This study investigates whether Cloprostenol, a synthetic prostaglandin analog, could protect against ischemia/reperfusion (IR) injury in rat ovaries. METHODS: Adult female rats were divided into four groups: Sham groups, ischemia (IS) groups, ischemia/reperfusion (IR) groups, and Cloprostenol-treated (CT) groups. The IR injury model was established by clamping the ovarian pedicle for a specified period, followed by reperfusion. The CT group received a pre-treatment of Cloprostenol before inducing ischemia. Ovarian tissues were collected for histological, and immunohistochemical examination. RESULTS: The IS group exhibited severe morphological damage to ovarian tissues, including disrupted tissue architecture and increased apoptosis (p < 0.001). In contrast, the CT group displayed significantly improved ovarian histology, with notable preservation of ovarian tissue and reduced apoptotic activity (p < 0.01). Immunohistochemical analysis revealed that the levels of 8-Hydroxy-2-deoxyguanosine (8-OHdG), Caspase 3, Cyclooxygenase 2 (COX-2), and Interleukin 1 beta (IL-1β) staining, which were elevated in the IS and IR groups, were significantly diminished in the CT group (p < 0.05). CONCLUSıON: Cloprostenol administration before IR injury in rat ovaries demonstrated a remarkable protective effect by improving histological damage and reducing DNA damage inflammation. These results highlight the therapeutic potential of Cloprostenol in safeguarding ovarian health against IR.
Competing Interests: Declaration of competing interest No conflict of interest is reported by the authors.
(Copyright © 2024 Elsevier B.V. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: